More importantly, the use of therapeutic drugs to inactivate NF-κB is currently a challenge, not only for the treatment of thyroid tumors but also for that of the majority of human cancers, so much so that the only anti-NF-κB drug approved in therapeutic regimens is bortezomib, whose employment is restricted to multiple myeloma. The gene discussed is NFKB1; the disease is plasma cell myeloma.